亚洲AV秘无码一区二区三区臀,免费中文字幕一级毛片

首頁> 產品列表> 抗體-藥物偶聯(lián)物/ ADC相關 ADC細胞毒素抑制劑>

澳瑞他汀E

NMR下載 COA and HPLC MSDS下載
names：
Auristatin E
CAS號：
160800-57-7
MDL Number： MFCD25976744
MF(分子式)： C40H69N5O7 MW(分子量)： 732.01
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11498622 Brand:BIOFOUNT

澳瑞他汀E(160800-57-7,Auristatin E)是dolastatin 10的合成類似物。澳瑞他汀E是高效的抗有絲分裂劑。澳瑞他汀E抑制微管蛋白聚合。澳瑞他汀E是一種具有細胞毒性的微管蛋白修飾劑，澳瑞他汀E具有有效的選擇性抗腫瘤活性。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000916-5mg	5mg	99.3%	￥ 7593.00	￥ 7593.00		2-3天	- +	￥ 0.00
YZM000916-1mg	1mg	99.3%	￥ 3412.00	￥ 3412.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	澳瑞他汀E(160800-57-7,Auristatin E),澳瑞他汀E抑制劑
英文別名	Auristatin E(160800-57-7)
CAS號	160800-57-7
Inchi	InChI=1S/C40H69N5O7/c1-14-26(6)35(44(11)40(50)33(24(2)3)42-39(49)34(25(4)5)43(9)10)31(51-12)23-32(46)45-22-18-21-30(45)37(52-13)27(7)38(48)41-28(8)36(47)29-19-16-15-17-20-29/h15-17,19-20,24-28,30-31,33-37,47H,14,18,21-23H2,1-13H3,(H,41,48)(H,42,49)/t26-,27+,28+,30-,31+,33-,34-,35-,36+,37+/m0/s1
InchiKey	WOWDZACBATWTAU-FEFUEGSOSA-N
分子式 Formula	C40H69N5O7
分子量 Molecular Weight	732.01
溶解度Solubility
性狀	淺黃色至黃色固體粉末
儲藏條件 Storage conditions	在-20°C條件下保存3年,在4°C條件下保存2年

澳瑞他汀E(160800-57-7,Auristatin E)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

Auristatin E(160800-57-7) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:澳瑞他汀E(160800-57-7,Auristatin E),澳瑞他汀E試劑,澳瑞他汀E抑制劑,澳瑞他汀E修飾劑,澳瑞他汀E的作用,澳瑞他汀E的合成,澳瑞他汀E的純度,澳瑞他汀E的質量,澳瑞他汀E的效果,澳瑞他汀E的使用,澳瑞他汀E的注意事項,澳瑞他汀E的生產

產品說明	澳瑞他汀E(160800-57-7,Auristatin E)是一種具有細胞毒性的微管蛋白修飾劑，澳瑞他汀E具有有效的選擇性抗腫瘤活性。
Introduction	Auristatin E (160800-57-7,澳瑞他汀E) is a cytotoxic tubulin modifier. Auristatin E has effective and selective anti-tumor activity.
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines PMID 27227324; Journal of immunotherapy (Hagerstown, Md. : 1997) 2016 Jul; 39(6):223-32 Name match

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells PMID 28216573; International journal of molecular sciences 2017 Feb; 18(2): Name matches: monomethyl auris

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer PMID 30725389; Investigational new drugs

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H1, Yu C2, Jiang J3, Huang C2, Yao X1, Xu Q2, Yu F2, Lou L4, Fang J1,5,6. Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6.
Antibody-drug conjugate (ADC) is a novel class of therapeutics for cancer target therapy. This study assessed antitumor activity of ADC with an antimitotic agent, monomethyl auristatin E (MMAE) and a humanized monoclonal anti-HER2 antibody, hertuzumab, in gastric cancer. The efficacy of hertuzumab-MC-Val-Cit-PAB-MMAE (hertuzumab-vcMMAE) on human epidermal growth factor receptor 2 (HER2) positive human gastric cancer cells, NCI-N87, was evaluated in vitro and in vivo. The cytotoxicity of hertuzumab was significantly enhanced after conjugation with MMAE. Compared to trastuzumab, hertuzumab had a higher affinity to HER2 and had more potent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. After conjugation with MMAE, the binding specificity for HER2 was not affected. Furthermore, the internalization of hertuzumab-vcMMAE in HER2 positive gastric cancer cells was verified. Although the conjugation of hertuzumab and MMAE decreased the ADCC effect, the overall cytotoxicity was dramatically increased in HER2 positive gastric cancer cells.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開